D. Boral Capital Reaffirms "Buy" Rating for Pulmonx (NASDAQ:LUNG)

D. Boral Capital restated their buy rating on shares of Pulmonx (NASDAQ:LUNG - Free Report) in a research note published on Thursday,Benzinga reports. D. Boral Capital currently has a $17.00 price objective on the stock.

Other research analysts also recently issued research reports about the company. Jefferies Financial Group started coverage on Pulmonx in a research note on Monday, March 10th. They issued a "buy" rating on the stock. Morgan Stanley assumed coverage on Pulmonx in a report on Monday, March 10th. They set an "equal weight" rating for the company. Finally, Citigroup began coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a "buy" rating on the stock. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $12.07.

Pulmonx Stock Down 3.5 %

Shares of Pulmonx stock traded down $0.13 during trading on Thursday, hitting $3.46. The company's stock had a trading volume of 158,865 shares, compared to its average volume of 313,360. Pulmonx has a 52 week low of $3.37 and a 52 week high of $10.01. The company has a market capitalization of $139.05 million, a PE ratio of -2.39 and a beta of 0.65. The company has a fifty day simple moving average of $6.32 and a two-hundred day simple moving average of $6.51. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $22.54 million for the quarter, compared to the consensus estimate of $22.03 million. Equities research analysts predict that Pulmonx will post -1.55 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Glendon E. French III sold 55,453 shares of the business's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the sale, the director now owns 1,011,974 shares of the company's stock, valued at approximately $8,379,144.72. The trade was a 5.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Geoffrey Beran Rose sold 5,779 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now owns 285,278 shares of the company's stock, valued at $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 145,660 shares of company stock worth $1,128,484 in the last three months. 6.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new position in shares of Pulmonx in the fourth quarter worth about $43,000. R Squared Ltd purchased a new position in shares of Pulmonx during the fourth quarter worth $46,000. ProShare Advisors LLC acquired a new position in Pulmonx in the 4th quarter valued at about $72,000. Stifel Financial Corp purchased a new stake in Pulmonx during the 4th quarter worth approximately $81,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Pulmonx in the first quarter valued at $82,000. Institutional investors and hedge funds own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.